Phase I/II Trial of Nano-camptothecin CRLX101 with Capecitabine and Radiotherapy as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

CRLX101 is a nanoparticle-drug conjugate with a camptothecin payload. We assessed the toxicity and pathologic complete response (pCR) rate of CRLX101 with standard neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer. A single-arm study was conducted with a 3+3 dose escalation phase...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nanomedicine
Main Authors: Sanoff, Hanna K., Moon, Dominic H., Moore, Dominic T., Boles, Jeremiah, Bui, Courtney, Blackstock, William, O’Neil, Bert H., Subramaniam, Somasundaram, McRee, Autumn J., Carlson, Cheryl, Lee, Michael S., Tepper, Joel E., Wang, Andrew Z.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7881832/
https://ncbi.nlm.nih.gov/pubmed/30858085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.nano.2019.02.021
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados